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Abstract: This ARISTOPHANES analysis examined stroke/systemic embolism (SE) and major
bleeding (MB) among a subgroup of nonvalvular atrial fibrillation (NVAF) patients with obesity
prescribed warfarin or non-vitamin K antagonist oral anticoagulants (NOACs) in order to inform
clinical decision making. A retrospective observational study was conducted among NVAF
patients who were obese and initiated apixaban, dabigatran, rivaroxaban, or warfarin from
1 January 2013–30 September 2015, with data pooled from CMS Medicare and four US commercial
claims databases. Propensity score matching was completed between NOACs and against warfarin in
each database, and the results were pooled. Cox models were used to evaluate the risks of stroke/SE
and MB. A total of 88,461 patients with obesity were included in the study. Apixaban and rivaroxaban
were associated with a lower risk of stroke/SE vs. warfarin (HR: 0.63, 95% CI: 0.49–0.82 and HR:
0.84, 95% CI: 0.72–0.98). Dabigatran was associated with a similar risk of stroke/SE compared to
warfarin. Compared with warfarin, apixaban and dabigatran had a lower risk of MB (HR: 0.54,
95% CI: 0.49–0.61 and HR: 0.75, 95% CI: 0.63–0.91). Rivaroxaban was associated with a similar risk of
MB compared to warfarin. In this high-risk population with obesity, NOACs had a varying risk of
stroke/SE and MB vs. warfarin.
Keywords: stroke; coagulation; outcomes; cardiovascular disease
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1. Introduction
Atrial fibrillation (AF) is the most common type of arrhythmia in the USA and European countries,
with a current estimated prevalence between 1% and 4% [1]. Its prevalence is of critical concern owing
to its cardiovascular complications such as ischemic stroke, heart failure, and increasing mortality [2].
Obesity, another prevalent condition worldwide, was estimated to cause 3.4 million deaths in 2010.
If current trends continue, forecasts estimate that 1 billion adults will be obese by the year 2030 [3].
Moreover, obesity has been linked with AF, due to its association with obstructive sleep apnea, diabetes
mellitus, hypertension, left ventricular dysfunction, heart failure with preserved left ventricular function,
and left atrial enlargement [4–6]. It has also been associated with hypofibrinolysis, inflammation, and a
prothrombotic state, further bolstering the link with the thromboembolic effects of AF [4,5].
In the Atherosclerosis Risk in Communities (ARIC) study, obesity and overweight accounted
for 17.9% of all AF cases [6]. Though AF risk appears to follow a linear relationship with an increase
in BMI, the pathophysiological basis of the obesity–AF relationship is complex and multifactorial [7].
Exploring the risk of stroke in a subgroup of an AF population with obesity is paramount due to
prevalence and the potential for high morbidity and mortality.
In the years since their approval, non-vitamin K oral anticoagulants (NOACs) have been
increasingly preferred over warfarin due to the convenience of fewer routine monitoring visits,
no requirements for dose adjustment, and limited dietary interactions. With the current fixed-dose
NOAC prescriptions, the clinical impact of anticoagulation on non-valvular atrial fibrillation (NVAF)
patients with obesity is expected to be similar, provided patients have optimum peak and trough levels
of NOACs [8]. The International Society of Thrombosis and Hemostasis recommends the standard
dosing of NOACs in patients with obesity and with a BMI ≤ 40 or weight ≤ 120 kg but suggests that
NOACs should not be used among patients with a BMI > 40 or weight > 120 kg because there is limited
clinical data for these patients [9,10]. The use of NOACs in patients with morbid obesity has not been
as well-documented or established. Therefore, comparing the risk of stroke and major bleeding (MB) in
a real-world population of NVAF patients with obesity and morbid obesity among oral anticoagulant
(OAC) users is crucial.
The NOAC clinical trials RE-LY and ROCKET-AF suggested that there was no significant interaction
between weight categories (≥100 kg vs. <100 kg) regarding the impact of dabigatran and rivaroxaban
versus warfarin on the risk of stroke/systemic embolism (SE) [11,12]. A similar risk of major and
clinically relevant non-MB was also seen among the subgroup with obesity for rivaroxaban vs. warfarin
in the ROCKET-AF trial [12]. A post-hoc analysis using the patients in the ARISTOTLE trial showed
evidence of significant interaction between BMI and MB, comparing apixaban vs. warfarin, with a
larger reduction in MB with normal vs. higher BMI [13].
Additionally, several observational studies evaluating patients with morbid obesity (BMI ≥ 35
or BMI ≥ 40, depending on the source) showed that NOACs had a similar risk of stroke/SE and MB
compared to warfarin [14–17]. While they add valuable knowledge regarding the clinical course of
patients with obesity and morbid obesity, existing real-world studies have limitations (e.g., small
sample size and no individual NOAC comparisons) that suggest the need for the further evaluation of
NOAC treatment in these populations. Larger real-world studies may be warranted to further examine
the use of NOACs in this high-risk population with obesity. Using several data sources, this subgroup
analysis of ARISTOPHANES (Anticoagulants for Reduction In Stroke: Observational Pooled analysis
on Health outcomes And Experience of Patients; NCT03087487) aimed to respectively compare the risk
of stroke/SE and MB among the NVAF population with obesity newly prescribed apixaban, dabigatran,
rivaroxaban, or warfarin.
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2. Experimental Section
2.1. Data Sources
This study was a retrospective observational database analysis of a patient population of
>180 million beneficiaries per year (~56% of the United States population), using fee-for-service
(FFS) Medicare data from the US Centers for Medicare & Medicaid Services (CMS) and four US
commercial claims databases: the IBM MarketScan® Commercial Claims and Encounter Database,
the IQVIA PharMetrics Plus™ Database, the Optum Clinformatics™ Data Mart, and the Humana
Research Database. The databases include patients with Medicare FFS, Medicare Advantage,
and commercial insurance. Database records include comprehensive demographic and clinical
information and International Classification of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) codes, Healthcare Common Procedure Coding System codes, and National Drug Codes.
Previously published articles include detailed descriptions of the datasets, the rationale for the
pooling process, and the approaches to minimizing potential patient record duplicates across data
sources [18,19].
2.2. Patient Selection
NVAF patients diagnosed with obesity were selected if they had ≥1 pharmacy claim
for apixaban, dabigatran, rivaroxaban, or warfarin between 01 January 2013 and 30 September
2015 (identification period). Edoxaban was excluded from the final sample due to small sample size.
Obesity is typically defined as a BMI ≥ 30 kg/m2 [20] and was defined here by the presence of a
diagnosis code containing obesity or an obese BMI designation (Table A1). The first NOAC prescription
date was designated as the index date if patients had a NOAC claim. The first warfarin prescription
date was designated as the index date for patients without any NOAC claim. Patients were required to
have an AF diagnosis before or on the index date and have continuous medical and pharmacy health
plan enrollment for ≥12 months pre-index date (baseline period).
To evaluate new initiators, patients treated with an OAC within 12 months pre-index date
were excluded. Patients were also excluded if they had claims indicating any of the following: valvular
heart disease, venous thromboembolism, transient AF (pericarditis, hyperthyroidism, or thyrotoxicity),
heart valve replacement/transplant, or cardiac surgery during the baseline period; pregnancy during the
study period; or hip or knee replacement surgery within 6 weeks pre-index date. In addition, patients
were excluded if they had >1 OAC on the index date or had no follow-up. Lastly, patients with claims
containing ICD-10 codes were excluded to ensure accurate classification, as the ICD-10-CM coding
system was not fully adopted in the United States until 1 October 2015, after the study period ended.
2.3. Outcome Measures
The outcome measures were time to first stroke/SE, including ischemic stroke, hemorrhagic stroke,
and SE; and time to first MB, including gastrointestinal (GI) bleeding, intracranial hemorrhage, and bleeding
at other key sites (e.g., the genitourinary tract, respiratory tract, or ocular area; Table A1) [21,22].
Outcomes were based on hospitalizations with stroke/SE or MB as the principal or first-listed
diagnosis. The follow-up period ranged from one day post-index date to 30 days after discontinuation,
the switch date, death (only inpatient death for the commercial databases and all-cause death for the
Medicare database), the end of continuous medical or pharmacy plan enrollment, or the end of the
study (30 September 2015), whichever came first.
2.4. Statistical Methods
Propensity score matching (PSM) was conducted between the NOAC and warfarin cohorts
(apixaban vs. warfarin, dabigatran vs. warfarin, and rivaroxaban vs. warfarin) and between the
NOAC cohorts (apixaban vs. dabigatran, apixaban vs. rivaroxaban, and dabigatran vs. rivaroxaban).
Patients were matched 1:1 in each dataset based on the propensity scores generated by logistic
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regression using demographics, Charlson comorbidity index scores [23], comorbidities, and baseline
co-medications. Patients were matched by nearest neighbor matching without replacement (with a
caliper of 0.01). Covariate balance was checked through standardized differences, with a threshold
of 10% [24]. After ensuring the cohorts were balanced in each database, study patients from the five
datasets were pooled for analysis.
The risks of stroke/SE and MB were evaluated using Cox proportional hazard models, with robust
sandwich estimates [25]. p-values < 0.05 were considered statistically significant. OAC treatment was
included as the independent variable; as the cohorts were balanced, no other covariates were included
in the model.
2.5. Subgroup Analyses
Two subgroup analyses were conducted. First, PSM and Cox proportional hazard models
were completed for patients prescribed standard dose NOACs (apixaban 5 mg twice a day (BID),
dabigatran 150 mg BID, rivaroxaban 20 mg once a day (QD)). A second subgroup analysis was
conducted among patients with morbid obesity. Patients with morbid obesity were defined using
diagnosis codes indicating morbid obesity or a BMI ≥ 40 and were re-matched (Table A1) [15]. For both
subgroup analyses, the same methodology as that for the main analysis was used.
Institutional Review Board approval was not required because the study did not involve
the collection, use, or transmittal of individual identifiable data. Both the datasets and the security of
the offices where analysis was completed (and where the datasets are kept) met the requirements of
the Health Insurance Portability and Accountability Act of 1996.
3. Results
After applying the selection criteria, a total of 88,461 (18.9%) NVAF patients with obesity
were identified, including 21,242 apixaban (24.0%), 7171 dabigatran (8.1%), 29,146 rivaroxaban (32.9%),
and 30,902 warfarin (34.9%) patients (Figure 1). Before PSM, the warfarin patients were the oldest
and had the highest CHA2DS2-VASc and HAS-BLED scores, followed by apixaban, rivaroxaban,
and dabigatran patients (Table A2).
The unadjusted incidence rates of stroke/SE were 2.0, 1.3, 1.5, and 1.3 for warfarin, apixaban,
dabigatran, and rivaroxaban per 100 person-years, respectively. The unadjusted rates for MB were 7.6,
3.9, 4.0, and 6.0 per 100 person-years for warfarin, apixaban, dabigatran, and rivaroxaban, respectively
(Table A3).
The PSM procedure resulted in 18,181 pairs for the apixaban-warfarin, 6646 pairs for the
dabigatran-warfarin, and 22,053 pairs for the rivaroxaban-warfarin cohorts with obesity. Matching for
NOAC comparisons included 6884 patient pairs for the apixaban-dabigatran, 20,431 pairs for the
apixaban-rivaroxaban, and 7103 pairs for the dabigatran-rivaroxaban cohorts (Figure 1). The mean
follow-up time for the six matched cohorts ranged from 6 to 8 months. Within NOAC vs. warfarin
comparisons, patients prescribed standard doses of NOACs included 84.8% of apixaban (5 mg),
86.5% of dabigatran (150 mg) and 75.3% of rivaroxaban (20 mg) patients. Select baseline characteristics
of the matched populations are shown in Table 1a,b. After matching, all demographic and clinical
characteristics were well balanced between pairs (a complete list of baseline variables appears in
Tables A4 and A5).
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Table 1. Baseline characteristics among NVAF patients with obesity after propensity score matching.
(A) Baseline Characteristics among NVAF Patients with Obesity after Propensity Score Matching—NOACs vs. Warfarin.
Apixaban Cohort Warfarin Cohort Dabigatran Cohort Warfarin Cohort Rivaroxaban Cohort Warfarin Cohort
n/Mean %/SD n/Mean %/SD n/Mean %/SD n/Mean %/SD n/Mean %/SD n/Mean %/SD
Sample Size 18,181 18,181 6646 6646 22,053 22,053
Age 72.8 9.0 72.7 8.8 70.7 9.1 70.9 9.3 72.3 8.8 72.3 8.9
Gender
Male 9260 50.9% 9268 51.0% 3632 54.6% 3633 54.7% 11,313 51.3% 11,372 51.6%
Female 8921 49.1% 8913 49.0% 3014 45.4% 3013 45.3% 10,740 48.7% 10,681 48.4%
Baseline Comorbidity
Deyo–Charlson Comorbidity Index 3.9 2.9 4.0 2.9 3.5 2.8 3.5 2.9 3.9 2.9 3.9 2.9
CHA2DS2-VASc Score 4.1 1.6 4.2 1.6 3.8 1.7 3.9 1.6 4.1 1.6 4.1 1.6
HAS-BLED Score 1 3.4 1.3 3.4 1.3 3.1 1.3 3.1 1.3 3.3 1.3 3.3 1.3
Dose of the Index Prescription
Standard Dose 2 15,410 84.8% 5747 86.5% 16,599 75.3%
Low Dose 3 2771 15.2% 899 13.5% 5454 24.7%
Follow-Up Time (in Days) 176.2 160.2 236.3 213.8 222.5 219.7 236.8 211.3 221.0 208.6 237.7 213.5
Median 120 157 128 159 142 159
(B) Baseline Characteristics among NVAF Patients with Obesity after Propensity Score Matching among NOACs vs. NOACs.
Apixaban Cohort Dabigatran Cohort Apixaban Cohort Rivaroxaban Cohort Dabigatran Cohort Rivaroxaban Cohort
n/Mean %/SD n/Mean %/SD n/Mean %/SD n/Mean %/SD n/Mean %/SD n/Mean %/SD
Sample Size 6884 6884 20,431 20,431 7103 7103
Age 70.5 10.0 70.0 9.8 71.5 9.8 71.5 9.7 69.7 10.0 69.5 9.9
Gender
Male 3776 54.9% 3810 55.3% 10,596 51.9% 10,614 52.0% 3982 56.1% 4171 58.7%
Female 3108 45.1% 3074 44.7% 9835 48.1% 9817 48.0% 3121 43.9% 2932 41.3%
Baseline Comorbidity
Deyo–Charlson Comorbidity Index 3.3 2.8 3.4 2.8 3.6 2.9 3.6 2.9 3.3 2.8 3.2 2.7
CHA2DS2-VASc Score 3.7 1.7 3.7 1.7 3.9 1.7 3.9 1.7 3.7 1.7 3.6 1.7
HAS-BLED Score 1 3.1 1.4 3.1 1.3 3.2 1.4 3.2 1.4 3.0 1.4 3.0 1.3
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Table 1. Cont.
Dose of the Index Prescription
Standard Dose 2 6045 87.8% 5979 86.9% 17,634 86.3% 15,514 75.9% 6194 87.2% 5698 80.2%
Low Dose 3 839 12.2% 905 13.1% 2797 13.7% 4917 24.1% 909 12.8% 1405 19.8%
Follow-Up Time (in Days) 176.2 158.3 221.5 218.3 176.1 159.6 220.4 208.6 220.7 218.1 217.4 206.4
Median 120 127 120 141 127 140
CHA2DS2-VASc: congestive heart failure, hypertension, aged ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, aged 65–74 years,
sex category; HAS-BLED: hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratios, elderly, drugs and alcohol; NOACs: non-vitamin K oral
anticoagulants; NVAF: non-valvular atrial fibrillation; SD: standard deviation. 1 As the INR value is not available in the databases, a modified HAS-BLED score was calculated with a
range of 0 to 8. 2 Standard dose: 5 mg apixaban, 150 mg dabigatran, 20 mg rivaroxaban. 3 Lower dose: 2.5 mg apixaban, 75 mg dabigatran, 10 or 15 mg rivaroxaban; (A) 1053 patients
treated with rivaroxaban were prescribed 10 mg rivaroxaban. (B) 950 and 310 patients were prescribed 10 mg of rivaroxaban in the apixaban-rivaroxaban and dabigatran-rivaroxaban
cohorts, respectively.
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3.1. NOAC vs. Warfarin Comparison
Patients prescribed apixaban and rivaroxaban had a lower risk of stroke/SE compared to warfarin
patients (apixaban: hazard ratio (HR): 0.63, 95% confidence interval (CI): 0.49–0.82; rivaroxaban:
HR: 0.84, 95% CI: 0.72–0.98), while dabigatran patients had a similar risk of stroke/SE compared to
warfarin patients (HR: 1.23, 95% CI: 0.90–1.67). Compared with warfarin, apixaban and dabigatran
(HR: 0.54, 95% CI: 0.49–0.61; HR: 0.75, 95% CI: 0.63–0.91, respectively) were associated with a lower
risk of MB (Figure 2a). Rivaroxaban had a similar risk of MB (HR: 1.02, 95% CI: 0.90–1.17) compared
to warfarin.
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3.2. NOAC vs. NOAC Comparisons
Compared to rivaroxaban, apixaban was associated with a lower risk of stroke/SE (HR: 0.78,
95% CI: 0.64–0.94) and MB (HR: 0.52, 95% CI: 0.47–0.59). Compared to dabigatran, apixaban had a
non-significant difference for the risk of stroke/SE (HR: 0.71, 95% CI: 0.49–1.04) and a lower risk of MB
(HR: 0.78, 95% CI: 0.61–0.99). Dabigatran was associated with a lower risk of MB (HR: 0.67, 95% CI:
0.56–0.81) than rivaroxaban while having a similar risk of stroke/SE (HR: 1.04, 95% CI: 0.72–1.51)
(Figure 2b). The Kaplan–Meier curves for the cumulative incidence rates of stroke/SE and MB in the
matched populations have been included in Figure A1(a)–(l)
3.3. Subgroup Analyses
The results of the standard dose subgroup analysis were generally consistent with the main analysis.
However, there was no significant difference between apixaban and dabigatran for major bleeding
(HR: 0.77, 95% CI: 0.59–1.00) and between apixaban and rivaroxaban for stroke/SE (HR: 0.93, 95% CI:
0.74–1.17). (Table 2).
Table 2. Incidence and hazard ratios of outcomes for standard-dosed NOACs vs. warfarin and NOACs
vs. NOACs.
NOACs vs. Warfarin NOACs vs. NOACs
Incidence per 100
person-years
Hazard Ratio
p-value Incidence per 100
person-years
Hazard Ratio
p-value
(95% CI) (95% CI)
5 mg
Apixaban
n = 15,364
Warfarin
n = 15,364
5 mg
Apixaban
n = 5904
150 mg
Dabigatran
n = 5904
Stroke/SE 1.2 1.9 0.61(0.46–0.81) 0.001 Stroke/SE 1.3 1.3
0.92
(0.55–1.52) 0.733
MB 4.0 6.3 0.57(0.51–0.64) <0.001 MB 3.0 3.7
0.77
(0.59–1.00) 0.052
150 mg
Dabigatran
n = 5756
Warfarin
n = 5756
5 mg
Apixaban
n = 16,553
20 mg
Rivaroxaban
n = 16,553
Stroke/SE 1.3 1.2 1.04(0.70–1.56) 0.843 Stroke/SE 1.2 1.2
0.93
(0.74–1.17) 0.524
MB 3.8 5.0 0.73(0.56–0.96) 0.024 MB 3.3 5.7
0.53
(0.47–0.60) <0.001
20 mg
Rivaroxaban
n = 17,123
Warfarin
n = 17,123
150 mg
Dabigatran
n = 6169
20 mg
Rivaroxaban
n = 6169
Stroke/SE 1.2 1.6 0.75(0.62–0.90) 0.002 Stroke/SE 1.3 1.1
1.18
(0.85–1.65) 0.322
MB 5.8 5.5 1.04(0.92–1.17) 0.550 MB 3.6 4.9
0.74
(0.61–0.89) 0.002
CI: confidence interval; MB: major bleeding; NOAC: non-vitamin K oral anticoagulants; SE: systemic embolism.
Among all the patients with obesity in the pooled sample, 39.5% were identified as morbidly obese.
PSM resulted in 6310 apixaban-warfarin, 2342 dabigatran-warfarin, 8055 rivaroxaban-warfarin,
2373 apixaban-dabigatran, 7180 apixaban-rivaroxaban, and 2617 dabigatran-rivaroxaban pairs
of patients. There was no significant difference in the risk of stroke/SE between each NOAC versus
warfarin or between NOACs. Apixaban had a lower risk of MB compared to warfarin, dabigatran,
and rivaroxaban. Conversely, dabigatran and rivaroxaban were both associated with a similar risk of
MB compared to warfarin in the population with morbid obesity (Table 3).
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Table 3. Incidence rates and hazard ratios of NOACs vs. warfarin and NOACs vs. NOACs among
patients with morbid obesity.
NOACs vs. Warfarin NOACs vs. NOACs
Incidence per 100
person-years
Hazard Ratio
p-value Incidence per 100
person-years
Hazard Ratio
p-value
(95% CI) (95% CI)
Apixaban Warfarin Apixaban Dabigatran
n = 6310 n = 6310 n = 2373 n = 2373
Stroke/SE 1.3 1.6
0.72
0.113 Stroke/SE 0.7 1.3
0.51
0.175(0.48–1.08) (0.19–1.35)
MB 4.6 7.8
0.53
<0.001 MB 3.9 5.6
0.63
0.011(0.44–0.64) (0.44–0.90)
Dabigatran Warfarin Apixaban Rivaroxaban
n = 2342 n = 2342 n = 7180 n = 7180
Stroke/SE 1.5 1.9
0.77
0.304 Stroke/SE 1.3 1.3
0.93
0.618(0.47–1.27) (0.68–1.26)
MB 5.7 7.4
0.76
0.088 MB 4.0 7.9
0.47
<0.001(0.56–1.04) (0.39–0.56)
Rivaroxaban Warfarin Dabigatran Rivaroxaban
n = 8055 n = 8055 n = 2617 n = 2617
Stroke/SE 1.3 1.8
0.72
0.079 Stroke/SE 1.4 1.3
1.13
0.629(0.50–1.04) (0.68–1.89)
MB 8.3 7.6
1.09
0.317 MB 5.4 6.7
0.79
0.086(0.92–1.28) (0.61–1.03)
CI: confidence interval; MB: major bleeding; NOAC: non-vitamin K oral anticoagulants; SE: systemic embolism.
4. Discussion
To date, this ARISTOPHANES obesity subgroup analysis is the largest retrospective observational
study evaluating the risk of stroke/SE and MB among NVAF patients with obesity who initiated
OAC treatment. Due to the increasing prevalence of obesity in the United States, the complexity of
case management, and the limited data, we chose to examine the effectiveness and safety of NOACs
within an NVAF sub-population with obesity [3,4]. With CMS Medicare and four large US national
claims datasets, this study found that NOACs had a varying risk of stroke/SE and MB compared to
warfarin and among each other in this population with obesity.
These results are largely consistent with subgroup analysis results from previous randomized
controlled trials (RCT)s. Post-hoc obesity analyses from the ARISTOTLE trial demonstrated that
BMI (18.5 to 25, 25 to 30, and ≥30) did not have significant interaction with treatment and stroke/SE,
death, or MACE (composite of stroke/SE, myocardial infarction, and death) [13]. However, the BMI
categories had a significant interaction with MB (Pinteraction = 0.006); for patients with a BMI ≥ 30,
apixaban had a similar risk of MB to warfarin; for patients with normal and overweight BMIs, the risk
of MB for apixaban was lower compared to that for warfarin. This trend was also seen in the other BMI
categories with varying levels of magnitude. The reason for this is likely multifactorial—it is possible
that differences in age and comorbidity levels may confound the risk of bleeding. Sub-analysis from
the RE-LY trial examined the effect of dabigatran on the risk of stroke/SE by weight categories (<50 kg,
50–99 kg and ≥100 kg). The interaction of the weight of patients on dabigatran (110 mg and 150 mg)
had no significant effect on the risk of stroke/SE (p = 0.48 and p = 0.42, respectively) [11]. Additionally,
sub-analysis from the ROCKET-AF trial showed no significant interaction between the BMI categories
and stroke/SE (p = 0.537) and MB outcomes (p = 0.310), comparing rivaroxaban and warfarin [12].
Therefore, based on weight or BMI, the referenced trials have demonstrated a similar efficacy and
risk of safety outcomes between NOACs and warfarin in a population with obesity. Furthermore,
in a meta-analysis of RCTs and observational studies among patients with obesity, NOACs showed a
similar risk of stroke/SE (HR: 0.84, 95% CI: 0.70–1.03) and MB (HR: 1.03, 95% CI: 0.90–1.18) compared
to warfarin [26].
Apart from RCTs, few real-world studies have compared the effectiveness and safety of OACs in
an NVAF population with obesity. Additionally, very few studies have compared NOACs individually
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rather than as a class. In the Dresden NOAC Registry, based in Germany, there was no indication that
increased BMI was associated with a lack of NOAC effectiveness or safety [27]. Just as for obesity,
very few studies have evaluated the effectiveness of NOACs in a population with morbid obesity.
A retrospective cohort study of 64 patients with morbid obesity (BMI > 40) found that NOACs had
a similar risk of ischemic stroke/transient ischemic attack and MB compared to warfarin [16]. In a
recent real-world analysis, the electronic medical records from patients with morbid obesity (BMI > 40)
at Montefiore Medical Center (NY, USA) suggested that apixaban had a similar risk of stroke and
bleeding compared to warfarin [14]. Another study from the Montefiore Medical Center found that
there was no significant difference in the incidence of stroke or major bleeding between apixaban,
rivaroxaban, and warfarin patients [17]. A recent real-world analysis using US Truven MarketScan
claims among NVAF patients with morbid obesity found that rivaroxaban showed a similar risk of
stroke and MB compared to warfarin [15]. Our analysis on patients with morbid obesity found a similar
risk of stroke/SE between NOACs and warfarin and suggested a lower risk of MB with apixaban vs.
warfarin, apixaban vs. dabigatran, and apixaban vs. rivaroxaban.
Prior studies have not evaluated the effect of dose among patients with obesity. In our dose
subgroup analysis, we found that standard dose apixaban and rivaroxaban were associated with a lower
risk of stroke/SE compared to warfarin, and standard-dose apixaban and dabigatran were associated
with a lower risk of MB compared to warfarin. In addition to this subgroup analysis, some real-world
studies have evaluated the effectiveness of fixed-dose NOACs in patients with obesity [28]. While
patients with obesity often require the dose adjustment of drugs due to altered pharmacokinetics,
the current recommendations for NOAC therapy imply fixed-dose treatment. Furthermore, it has
been found that while the plasma levels of NOACs varied by body weight, the variance was not
significant [28]. Further studies are needed to evaluate the use of standard-dose NOACs among
patients with obesity.
Compared to previous studies that evaluated the safety and effectiveness of NOACs among NVAF
patients with obesity, the ARISTOPHANES pooled study provided a larger sample size with higher
statistical power to compare outcomes for each OAC in the NVAF subgroup with obesity. The study
findings showed that in this high-risk subgroup of NVAF patients, apixaban and rivaroxaban patients
had a lower risk of stroke/SE compared to warfarin patients, and rivaroxaban had a similar risk of MB
compared to warfarin. Compared with warfarin, apixaban and dabigatran were associated with a
lower risk of MB, while dabigatran patients had a similar risk of stroke/SE. In addition, the study found
that compared to dabigatran, apixaban had a non-significant difference for the risk of stroke/SE and
had a lower risk of MB. Apixaban patients were also found to have a lower risk of stroke/SE and MB
compared to rivaroxaban patients. Dabigatran was associated with a lower risk of MB and a similar risk
of stroke/SE when compared to rivaroxaban. These results provide information complementary to the
obesity post-hoc and sub-analyses from existing trials. While hypothesis-generating, this real-world
evidence supports the fixed dose regimen of NOACs, which appears to maintain safety and effectiveness
compared to traditional vitamin K antagonist therapy.
5. Limitations
This retrospective observational study has several limitations. First, only statistical associations
could be concluded, not causal relationships. Although cohorts were matched through PSM, there
were potential residual confounders. This limitation is especially important for interpreting the
NOAC vs. NOAC comparison results, which are intended for hypothesis generation, given the lack of
head-to-head trials. In addition, since the two drug cohorts were matched independently, conclusions
can only be drawn between the matched cohorts, not across the comparisons. Second, due to the
nature of the claims studies, outcome measures could only be based on ICD-9-CM codes without
further adjustment with precise clinical criteria. More importantly, obesity indicators were ascertained
based on ICD-9-CM coding (for ≥30 BMI or an indication of obesity). Body measurements such as
weight or lean body mass were not available in the claims data. A separate analysis was conducted
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to validate the diagnosis codes used to identify obesity and morbid obesity in this study by using
one of the five databases linked with electronic medical records [29]. The results from that study
showed the obesity diagnosis codes had high positive predictive value (PPV) (89.8%), high specificity
(95.2%), and modest sensitivity (48.7%) among newly treated NVAF patients. The morbid obesity
diagnosis codes also had high specificity (96.5%) but modest PPV (67.9%) and sensitivity (62.8%) [29].
The modest sensitivity suggests that we may fail to identify some of the patients with obesity and
morbid obesity. The moderate PPV for the morbid obesity diagnosis codes indicates that there may be
some misclassified patients in this group.
An additional study limitation is that laboratory values—such as international normalized ratio
(INR) measurements—are not available in the dataset, so the time in the therapeutic range for the
patients prescribed warfarin was indeterminable. Nonetheless, the inclusion of patients with potentially
poorer quality control of warfarin therapy in everyday clinical practice may enable the study findings
to better reflect real-world situations. Additionally, unobserved heterogeneity may exist across the
five data sources. Finally, the results may not reflect the overall NVAF population in the United States
because the study did not include uninsured patients and patients solely covered by other public
health insurance plans.
6. Conclusions
This study, the largest observational study of NVAF patients with obesity, shows that NOACs
were associated with a varying risk of stroke/SE and MB compared to warfarin and among each other.
Apixaban was associated with a lower risk of stroke/SE and MB compared to warfarin. Additionally,
compared with warfarin, dabigatran was associated with a lower risk of MB and a similar risk of
stroke/SE; rivaroxaban was associated with a lower risk of stroke/SE and a similar risk of MB. Additional
real-world studies are warranted in the population with obesity to understand the impact of NOACs
on this high-risk group. These findings may help clinicians better understand the differentiated profile
of OACs in an NVAF patient population with obesity.
Author Contributions: Conceptualization, all authors.; methodology, A.K. (Allison Keshishian); software, A.K.
(Allison Keshishian), S.D., H.Y., and G.Y.H.L.; validation, A.K. (Allison Keshishian); formal analysis, A.K.
(Allison Keshishian); investigation, all authors; resources, A.K. (Allison Keshishian), S.D., H.Y., and G.Y.H.L.;
data curation, A.K. (Allison Keshishian); writing—original draft preparation, A.K. (Allison Keshishian);
writing—review and editing, all authors; visualization, A.K. (Allison Keshishian); supervision, S.D., H.Y., G.Y.H.L.;
project administration, S.D., H.Y., G.Y.H.L.; funding acquisition, A.K. (Amiee Kang), A.D.D., X.L. (Xuemei Luo),
X.L. (Xiaoyan Li), N.B., L.R., J.M., X.P., M.D.F., and A.B.G.R. All authors have read and agreed to the published
version of the manuscript.
Funding: This study was funded by Pfizer Inc and Bristol-Myers Squibb.
Conflicts of Interest: SD is a consultant for Bristol Myers Squibb Company/Pfizer Inc., Daiichi-Sankyo, Portola, and
Boehringer Ingelheim, and has been on the speakers’ bureau for Janssen, Bristol Myers Squibb Company/Pfizer Inc.,
and Boehringer Ingelheim. A Keshishian is a paid employee of STATinMED Research, which is a paid consultant to
Pfizer and Bristol-Myers Squibb. A Kang, X Li, ADD, NB, LR, XP, and ABGR are paid employees of Bristol-Myers
Squibb. X Luo, MDF, and JM are paid employees of Pfizer Inc. GYH Lip is a consultant for Bayer/Janssen,
BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo. Speaker for Bayer,
BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally.
J. Clin. Med. 2020, 9, 1633 13 of 25
Appendix A
Table A1. ICD-9-CM diagnosis and procedure codes for selection criteria and outcomes.
Diagnosis ICD-9-CM Diagnosis and Procedure Codes
Selection Criteria
Atrial Fibrillation 427.31
Valvular Heart Disease 394.0, 394.1, 394.2, 394.9, 396.0, 396.1, 396.8, 396.9,424.0, 745.xx
Heart Valve Replacement V42.2, V43.3, 35.05–35.09, 35.20–35.28, 35.97
VTE 451–453, 671.3, 671.4, 671.9, 415.1, 673.2, 673.8
Transient AF (Heart Valve Replacement/Transplant,
Pericarditis, Thyrotoxicity)
Pericarditis: 006.8, 017.9, 036.41, 074.21, 093.81, 098.83,
115.93, 390, 391, 392.0, 393, 411.0, 420.90, 420.91,
420.99, 423.0, 423.1, 423.2, 423.8, 423.9
Thyrotoxicity: 242.0, 242.1, 242.2, 242.3, 242.4, 242.8,
242.9
Pregnancy
ICD-9-CM: 630–679, V22, V23, V24, V27, V28, V61.6,
V61.7, 792.3, 796.5, 72–75.99
HCPCS: 59000–59350, 76801–76828, 83661–83664
Obesity
278.00 (obesity, unspecified), 278.01 (morbid obesity),
278.03 (obesity hypoventilation syndrome), V85.3
(BMI of 30–39), V85.4 (BMI 40 and over)
Morbid Obesity 278.01 (morbid obesity), V85.4 (BMI 40 and over)
Outcomes
Hemorrhagic Stroke 430.xx–432.xx
Cases were excluded if traumatic brain injury
(ICD-9-CM: 800–804, 850–854) was present during
hospitalization.
Ischemic Stroke 433.x1, 434.x1, 436
Systemic Embolism 444.x, 445.x
Major Gastrointestinal Bleeding
456.0, 456.20, 530.82, 531.0x, 531.2x, 531.4x, 531.6x,
532.0x, 532.2x, 532.4x, 532.6x, 533.0x, 533.2x, 533.4x,
533.6x, 534.0x, 534.2x, 534.4x, 534.6x, 535.01, 535.11,
535.21, 535.31, 535.41, 535.51, 535.61, 537.83, 562.02,
562.03, 562.12, 562.13, 568.81, 569.3, 569.85, 578.x
Procedure code: 44.43
Major Intracranial Hemorrhage 430, 431, 432.0, 432.1, 432.9, 852.0x, 852.2x, 852.4x,853.0x,
Major Other Hemorrhage
285.1, 360.43, 362.43, 362.81, 363.61, 363.62, 363.72,
364.41, 372.72, 374.81, 376.32, 377.42, 379.23, 423.0x,
596.7x, 599.7x, 602.1x, 620.1, 621.4, 626.2, 626.5, 626.7,
626.8, 626.9, 719.1x, 782.7, 784.7, 784.8, 786.3x, 958.2,
997.02, 998.11
Procedure code: 99.04
AF: atrial fibrillation; BMI: body mass index; HCPCS: Healthcare Common Procedural Coding System; ICD-9:
International Classifications of Diseases, Ninth Edition; VTE: venous thromboembolism.
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Table A2. Baseline characteristics of NVAF patients with obesity before PSM.
Warfarin Cohort Apixaban Cohort Dabigatran Cohort Rivaroxaban Cohort
n/Mean %/SD n/Mean %/SD n/Mean %/SD n/Mean %/SD
Sample Size 30,902 21,242 7171 29,146
Age 72.8 8.8 71.5 9.9 69.6 10.0 70.0 10.3
18–54 1038 3.4% 1285 6.0% 606 8.5% 2346 8.0%
55–64 2895 9.4% 2793 13.1% 1112 15.5% 4636 15.9%
65–74 14,044 45.4% 8977 42.3% 3215 44.8% 12,486 42.8%
≥75 12,925 41.8% 8187 38.5% 2238 31.2% 9678 33.2%
Gender
Male 15,974 51.7% 11,027 51.9% 4033 56.2% 15,647 53.7%
Female 14,928 48.3% 10,215 48.1% 3138 43.8% 13,499 46.3%
U.S. Geographic Region
Northeast 5330 17.2% 3405 16.0% 1367 19.1% 4944 17.0%
Midwest 9934 32.1% 4980 23.4% 1701 23.7% 7372 25.3%
South 10,693 34.6% 10,103 47.6% 3017 42.1% 12,705 43.6%
West 4857 15.7% 2676 12.6% 1052 14.7% 3988 13.7%
Other 88 0.3% 78 0.4% 34 0.5% 137 0.5%
Race (only for Humana
and Medicare)
White 21,856 88.2% 14,231 89.1% 4376 88.0% 18,059 88.5%
Black 1917 7.7% 1031 6.5% 328 6.6% 1277 6.3%
Other 1004 4.1% 711 4.5% 270 5.4% 1075 5.3%
Baseline Comorbidity
Deyo–Charlson
Comorbidity Index 4.5 3.1 3.7 2.9 3.3 2.8 3.4 2.8
CHADS2 Score 2.8 1.3 2.5 1.3 2.4 1.3 2.4 1.3
0 567 1.8% 594 2.8% 262 3.7% 1031 3.5%
1 3942 12.8% 4185 19.7% 1572 21.9% 6374 21.9%
2 8708 28.2% 6475 30.5% 2354 32.8% 9320 32.0%
3+ 17,685 57.2% 9988 47.0% 2983 41.6% 12,421 42.6%
CHA2DS2-VASc Score 4.3 1.6 3.9 1.7 3.7 1.7 3.7 1.7
0 254 0.8% 349 1.6% 169 2.4% 646 2.2%
1 796 2.6% 1045 4.9% 506 7.1% 1936 6.6%
2 2669 8.6% 2842 13.4% 1112 15.5% 4466 15.3%
3 5836 18.9% 4464 21.0% 1610 22.5% 6305 21.6%
4+ 21,347 69.1% 12,542 59.0% 3774 52.6% 15,793 54.2%
HAS-BLED Score 3.5 1.4 3.2 1.4 3.0 1.4 3.1 1.4
0 246 0.8% 281 1.3% 133 1.9% 553 1.9%
1 1501 4.9% 1728 8.1% 787 11.0% 2993 10.3%
2 5661 18.3% 4657 21.9% 1793 25.0% 6992 24.0%
3+ 23,494 76.0% 14,576 68.6% 4458 62.2% 18,608 63.8%
Bleeding History 8496 27.5% 4425 20.8% 1329 18.5% 5822 20.0%
Congestive Heart
Failure 14,722 47.6% 8068 38.0% 2487 34.7% 10,246 35.2%
Diabetes Mellitus 18,984 61.4% 11,390 53.6% 3778 52.7% 15,164 52.0%
Hypertension 29,379 95.1% 20,022 94.3% 6670 93.0% 27,161 93.2%
Renal Disease 12,934 41.9% 6445 30.3% 1720 24.0% 7489 25.7%
Liver Disease 2382 7.7% 1471 6.9% 472 6.6% 2051 7.0%
Myocardial Infarction 4905 15.9% 2528 11.9% 722 10.1% 3235 11.1%
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Table A2. Cont.
Warfarin Cohort Apixaban Cohort Dabigatran Cohort Rivaroxaban Cohort
n/Mean %/SD n/Mean %/SD n/Mean %/SD n/Mean %/SD
Dyspepsia or Stomach
Discomfort 7974 25.8% 5014 23.6% 1555 21.7% 6711 23.0%
Non-Stroke/SE
Peripheral Vascular
Disease
19,062 61.7% 11,847 55.8% 3745 52.2% 15,274 52.4%
Stroke/SE 4669 15.1% 2307 10.9% 723 10.1% 2937 10.1%
Transient Ischemic
Attack 2295 7.4% 1397 6.6% 445 6.2% 1787 6.1%
Anemia and
Coagulation Defects 12,178 39.4% 6478 30.5% 1845 25.7% 7949 27.3%
Alcoholism 788 2.5% 517 2.4% 203 2.8% 874 3.0%
Peripheral Artery
Disease 8357 27.0% 4563 21.5% 1339 18.7% 6000 20.6%
Coronary Artery
Disease 16,865 54.6% 10,616 50.0% 3315 46.2% 13,513 46.4%
Dyslipidemia 25,528 82.6% 17,510 82.4% 5775 80.5% 23,533 80.7%
Morbid Obesity 12,779 41.4% 7962 37.5% 2752 38.4% 11,447 39.3%
Baseline Medication
Use
ACEi/ARB 21,240 68.7% 14,912 70.2% 4964 69.2% 20,093 68.9%
Amiodarone 4143 13.4% 2839 13.4% 859 12.0% 3576 12.3%
Beta Blockers 19,252 62.3% 13,486 63.5% 4347 60.6% 18,192 62.4%
H2-Receptor Antagonist 2663 8.6% 1569 7.4% 485 6.8% 2081 7.1%
Proton Pump Inhibitor 10,973 35.5% 7530 35.4% 2354 32.8% 9922 34.0%
Statins 20,288 65.7% 13,579 63.9% 4324 60.3% 17,928 61.5%
Anti-Platelets 6869 22.2% 4597 21.6% 1244 17.3% 5488 18.8%
NSAIDS 8019 25.9% 6379 30.0% 2194 30.6% 9165 31.4%
Dose of the Index
Prescription
Standard Dose 1 18,290 86.1% 6254 87.2% 22,908 78.6%
Lower Dose 2 2952 13.9% 917 12.8% 6238 21.4%
Follow-up Time (in
Days) 232.4 211.1 175.6 159.1 220.5 217.9 217.9 206.4
Median 154 120 126 139
ACEi/ARB: angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; CHA2DS2-VASc: congestive
heart failure, hypertension, aged ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack or
thromboembolism, vascular disease, aged 65–74 years, sex category; HAS-BLED: hypertension, abnormal
renal and liver function, stroke, bleeding, labile international normalized ratios, elderly, drugs and alcohol;
NSAIDs: non-steroidal anti-inflammatory drugs; NVAF: nonvalvular atrial fibrillation; PSM: propensity score
matching; SD: standard deviation; SE: systemic embolism. 1 Standard dose: 5 mg apixaban, 150 mg dabigatran,
20 mg rivaroxaban. 2 Lower dose: 2.5 mg apixaban, 75 mg dabigatran, 10 or 15 mg rivaroxaban; 1311 patients were
prescribed 10 mg of rivaroxaban in the rivaroxaban cohort.
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Table A3. Outcomes characteristics of NVAF patients before PSM.
Warfarin Cohort Apixaban Cohort Dabigatran Cohort Rivaroxaban Cohort
n/Mean %/SD n/Mean %/SD n/Mean %/SD n/Mean %/SD
Sample Size 30,902 21,242 7171 29,146
Discontinuation 17,553 56.8% 8035 37.8% 4100 57.2% 14,575 50.0%
Time-to-Discontinuation 165.3 163.8 114.9 117.0 141.4 152.7 143.6 153.1
Switch 787 3.7% 748 10.4% 1972 6.8%
Time-to-Switch 94.8 103.0 116.2 136.2 122.7 142.4
Stroke/SE 1 406 1.3% 132 0.6% 67 0.9% 226 0.8%
Hemorrhagic Stroke 115 0.4% 23 0.1% 41 0.1%
Ischemic Stroke 276 0.9% 107 0.5% 56 0.8% 170 0.6%
Systemic Embolism 20 0.1% 17 0.1%
Major Bleeding 1491 4.8% 399 1.9% 174 2.4% 1050 3.6%
Gastrointestinal Bleeding 721 2.3% 195 0.9% 110 1.5% 612 2.1%
Intracranial Hemorrhage 190 0.6% 38 0.2% 17 0.2% 67 0.2%
Other Sites 676 2.2% 187 0.9% 55 0.8% 447 1.5%
Stroke/SE Incidence Rate
(per 100 person-years) 2.0 1.3 1.5 1.3
Major Bleeding Incidence
Rate (per 100 person-years) 7.6 3.9 4.0 6.0
NVAF: nonvalvular atrial fibrillation; PSM: propensity score matching; SD: standard deviation; SE: systemic embolism.
1 For some cohorts, the number of patients with a stroke event is <11, which cannot be presented per the data
use agreement.
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Table A4. Baseline characteristics among NVAF patients with obesity after propensity score matching—NOACs vs. warfarin.
Warfarin Cohort Apixaban Cohort Warfarin Cohort Dabigatran Cohort Warfarin Cohort Rivaroxaban Cohort
n/Mean %/SD n/Mean %/SD STD 1 n/Mean %/SD n/Mean %/SD STD 1 n/Mean %/SD n/Mean %/SD STD 1
Sample Size 18,181 18,181 6646 6646 22,053 22,053
Age 2 72.7 8.8 72.8 9.0 1.52 70.9 9.3 70.7 9.1 1.51 72.3 8.9 72.3 8.8 0.21
18–54 655 3.6% 659 3.6% 0.12 370 5.6% 391 5.9% 1.36 865 3.9% 828 3.8% 0.87
55–64 1746 9.6% 1709 9.4% 0.69 901 13.6% 879 13.2% 0.97 2197 10.0% 2210 10.0% 0.20
65–74 8192 45.1% 8184 45.0% 0.09 3120 46.9% 3147 47.4% 0.81 10,347 46.9% 10,360 47.0% 0.12
≥75 7588 41.7% 7629 42.0% 0.46 2255 33.9% 2229 33.5% 0.83 8644 39.2% 8655 39.2% 0.10
Gender 2
Male 9268 51.0% 9260 50.9% 0.09 3633 54.7% 3632 54.6% 0.03 11,372 51.6% 11,313 51.3% 0.54
Female 8913 49.0% 8921 49.1% 0.09 3013 45.3% 3014 45.4% 0.03 10,681 48.4% 10,740 48.7% 0.54
U.S. Geographic Region 2
Northeast 3132 17.2% 3137 17.3% 0.07 1264 19.0% 1244 18.7% 0.77 3776 17.1% 3828 17.4% 0.62
Midwest 4588 25.2% 4608 25.3% 0.25 1640 24.7% 1624 24.4% 0.56 6275 28.5% 6174 28.0% 1.02
South 7908 43.5% 7834 43.1% 0.82 2643 39.8% 2724 41.0% 2.48 8560 38.8% 8624 39.1% 0.60
West 2501 13.8% 2553 14.0% 0.83 1073 16.1% 1024 15.4% 2.02 3377 15.3% 3365 15.3% 0.15
Other 52 0.3% 49 0.3% 0.31 26 0.4% 30 0.5% 0.93 65 0.3% 62 0.3% 0.25
Race (Only for Humana and Medicare) 2
White 13,165 89.0% 13,190 89.2% 0.54 4367 88.8% 4338 88.2% 1.85 15,805 88.9% 15,796 88.9% 0.16
Black 1010 6.8% 981 6.6% 0.78 298 6.1% 324 6.6% 2.17 1158 6.5% 1178 6.6% 0.45
Other 619 4.2% 623 4.2% 0.13 251 5.1% 254 5.2% 0.28 812 4.6% 801 4.5% 0.30
Baseline Comorbidity
Deyo–Charlson Comorbidity Index 2 4.0 2.9 3.9 2.9 0.92 3.5 2.9 3.5 2.8 3.05 3.9 2.9 3.9 2.9 0.27
CHA2DS2-VASc Score 4.2 1.6 4.1 1.6 0.61 3.9 1.6 3.8 1.7 1.99 4.1 1.6 4.1 1.6 0.12
0 198 1.1% 165 0.9% 1.83 96 1.4% 107 1.6% 1.35 229 1.0% 222 1.0% 0.32
1 544 3.0% 565 3.1% 0.67 313 4.7% 324 4.9% 0.77 731 3.3% 751 3.4% 0.50
2 1848 10.2% 2029 11.2% 3.23 880 13.2% 951 14.3% 3.10 2306 10.5% 2540 11.5% 3.39
3 3729 20.5% 3718 20.4% 0.15 1559 23.5% 1534 23.1% 0.89 4775 21.7% 4596 20.8% 1.98
4+ 11,862 65.2% 11,704 64.4% 1.82 3798 57.1% 3730 56.1% 2.06 14,012 63.5% 13,944 63.2% 0.64
HAS-BLED Score 3 3.4 1.3 3.4 1.3 0.54 3.1 1.3 3.1 1.3 1.47 3.3 1.3 3.3 1.3 0.39
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Table A4. Cont.
Warfarin Cohort Apixaban Cohort Warfarin Cohort Dabigatran Cohort Warfarin Cohort Rivaroxaban Cohort
n/Mean %/SD n/Mean %/SD STD 1 n/Mean %/SD n/Mean %/SD STD 1 n/Mean %/SD n/Mean %/SD STD 1
0 184 1.0% 144 0.8% 2.33 96 1.4% 93 1.4% 0.38 224 1.0% 198 0.9% 1.21
1 991 5.5% 1063 5.8% 1.72 567 8.5% 565 8.5% 0.11 1289 5.8% 1402 6.4% 2.14
2 3799 20.9% 3696 20.3% 1.40 1585 23.8% 1631 24.5% 1.62 4851 22.0% 4738 21.5% 1.24
3+ 13,207 72.6% 13,278 73.0% 0.88 4398 66.2% 4357 65.6% 1.30 15,689 71.1% 15,715 71.3% 0.26
Bleeding History 2 4171 22.9% 4127 22.7% 0.58 1346 20.3% 1294 19.5% 1.96 5015 22.7% 5046 22.9% 0.33
Congestive Heart Failure 2 7553 41.5% 7485 41.2% 0.76 2436 36.7% 2424 36.5% 0.37 8926 40.5% 8877 40.3% 0.45
Diabetes Mellitus 2 10,265 56.5% 10,297 56.6% 0.36 3716 55.9% 3611 54.3% 3.18 12,438 56.4% 12,435 56.4% 0.03
Hypertension 2 17,276 95.0% 17,273 95.0% 0.08 6235 93.8% 6223 93.6% 0.74 20,842 94.5% 20,833 94.5% 0.18
Renal Disease 2 6173 34.0% 6166 33.9% 0.08 1758 26.5% 1697 25.5% 2.09 6893 31.3% 6891 31.2% 0.02
Liver Disease 2 1280 7.0% 1271 7.0% 0.19 472 7.1% 453 6.8% 1.12 1601 7.3% 1620 7.3% 0.33
Myocardial Infarction 2 2369 13.0% 2343 12.9% 0.43 700 10.5% 711 10.7% 0.54 2771 12.6% 2794 12.7% 0.31
Dyspepsia or Stomach Discomfort 2 4502 24.8% 4430 24.4% 0.92 1486 22.4% 1488 22.4% 0.07 5375 24.4% 5390 24.4% 0.16
Non-Stroke/SE Peripheral Vascular
Disease 2 10,753 59.1% 10,676 58.7% 0.86 3639 54.8% 3624 54.5% 0.45 12,750 57.8% 12,759 57.9% 0.08
Stroke/SE 2 2273 12.5% 2183 12.0% 1.51 739 11.1% 710 10.7% 1.40 2699 12.2% 2639 12.0% 0.83
Transient Ischemic Attack 2 1278 7.0% 1257 6.9% 0.45 456 6.9% 432 6.5% 1.45 1511 6.9% 1510 6.8% 0.02
Anemia and Coagulation Defects 2 6164 33.9% 6082 33.5% 0.95 1874 28.2% 1814 27.3% 2.02 7167 32.5% 7105 32.2% 0.60
Alcoholism 2 428 2.4% 429 2.4% 0.04 192 2.9% 182 2.7% 0.91 621 2.8% 620 2.8% 0.03
Peripheral Artery Disease 4513 24.8% 4228 23.3% 3.67 1464 22.0% 1319 19.8% 5.36 5287 24.0% 5282 24.0% 0.05
Coronary Artery Disease 9491 52.2% 9544 52.5% 0.58 3168 47.7% 3197 48.1% 0.87 11,153 50.6% 11,261 51.1% 0.98
Dyslipidemia 2 15,199 83.6% 15,191 83.6% 0.12 5419 81.5% 5402 81.3% 0.66 18,168 82.4% 18,237 82.7% 0.82
Morbid Obesity 7207 39.6% 6777 37.3% 4.86 2619 39.4% 2523 38.0% 2.97 8782 39.8% 8660 39.3% 1.13
Baseline Medication Use 2
ACEi/ARB 12,771 70.2% 12,788 70.3% 0.20 4615 69.4% 4651 70.0% 1.18 15,371 69.7% 15,345 69.6% 0.26
Amiodarone 2429 13.4% 2446 13.5% 0.27 810 12.2% 810 12.2% 0.00 2793 12.7% 2816 12.8% 0.31
Beta Blockers 11,442 62.9% 11,562 63.6% 1.37 4051 61.0% 4025 60.6% 0.80 13,732 62.3% 13,778 62.5% 0.43
H2-Receptor Antagonist 1438 7.9% 1419 7.8% 0.39 500 7.5% 464 7.0% 2.09 1735 7.9% 1760 8.0% 0.42
Proton Pump Inhibitor 6477 35.6% 6510 35.8% 0.38 2259 34.0% 2229 33.5% 0.95 7725 35.0% 7755 35.2% 0.29
Statins 11,915 65.5% 11,913 65.5% 0.02 4213 63.4% 4111 61.9% 3.17 14,141 64.1% 14,210 64.4% 0.65
Anti-Platelets 4070 22.4% 4066 22.4% 0.05 1195 18.0% 1215 18.3% 0.78 4606 20.9% 4585 20.8% 0.23
NSAIDS 5211 28.7% 5255 28.9% 0.53 2025 30.5% 2016 30.3% 0.29 6384 28.9% 6408 29.1% 0.24
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Table A4. Cont.
Warfarin Cohort Apixaban Cohort Warfarin Cohort Dabigatran Cohort Warfarin Cohort Rivaroxaban Cohort
n/Mean %/SD n/Mean %/SD STD 1 n/Mean %/SD n/Mean %/SD STD 1 n/Mean %/SD n/Mean %/SD STD 1
Dose of the Index Prescription
Standard Dose 4 15,410 84.8% 5747 86.5% 16,599 75.3%
Low Dose 5 2771 15.2% 899 13.5% 5454 24.7%
Follow-Up Time (in Days) 236.3 213.8 176.2 160.2 31.85 236.8 211.3 222.5 219.7 6.60 237.7 213.5 221.0 208.6 7.92
Median 157 120 159 128 159 142
ACEi/ARB: angiotensin converting enzyme inhibitors/angiotensin-receptor blockers; CHA2DS2-VASc: congestive heart failure, hypertension, aged ≥75 years, diabetes mellitus, prior
stroke or transient ischemic attack or thromboembolism, vascular disease, aged 65–74 years, sex category; HAS-BLED: hypertension, abnormal renal and liver function, stroke, bleeding,
labile international normalized ratios, elderly, drugs and alcohol; NOACs: non-vitamin K oral anticoagulants; NSAIDs: non-steroidal anti-inflammatory drugs; NVAF: non-valvular atrial
fibrillation; SD: standard deviation; SE: systemic embolism; STD: standardized difference. 1 Std difference = 100 ×|actual std diff|. Std difference greater than 10 is considered significant.
2 Variables used in propensity score matching. 3 As the INR value is not available in the databases, a modified HAS-BLED score was calculated with a range of 0 to 8. 4 Standard dose:
5 mg apixaban, 150 mg dabigatran, 20 mg rivaroxaban. 5 Lower dose: 2.5 mg apixaban, 75 mg dabigatran, 10 or 15 mg rivaroxaban; 1053 patients treated with rivaroxaban were prescribed
10 mg rivaroxaban.
Table A5. Baseline characteristics among NVAF patients with obesity after propensity score matching among NOACs vs. NOACs.
Apixaban Cohort Dabigatran Cohort Apixaban Cohort Rivaroxaban Cohort Dabigatran Cohort Rivaroxaban Cohort
n/Mean %/SD n/Mean %/SD STD 1 n/Mean %/SD n/Mean %/SD STD 1 n/Mean %/SD n/Mean %/SD STD 1
Sample Size 6884 6884 20,431 20,431 7103 7103
Age 2 70.5 10.0 70.0 9.8 4.23 71.5 9.8 71.5 9.7 0.85 69.7 10.0 69.5 9.9 1.40
18–54 510 7.4% 521 7.6% 0.61 1200 5.9% 1215 5.9% 0.31 590 8.3% 581 8.2% 0.46
55–64 980 14.2% 988 14.4% 0.33 2586 12.7% 2599 12.7% 0.19 1102 15.5% 1102 15.5% 0.00
65–74 3069 44.6% 3159 45.9% 2.63 8828 43.2% 8689 42.5% 1.37 3193 45.0% 3366 47.4% 4.89
≥75 2325 33.8% 2216 32.2% 3.37 7817 38.3% 7928 38.8% 1.12 2218 31.2% 2054 28.9% 5.04
Gender 2
Male 3776 54.9% 3810 55.3% 0.99 10,596 51.9% 10,614 52.0% 0.18 3982 56.1% 4171 58.7% 5.38
Female 3108 45.1% 3074 44.7% 0.99 9835 48.1% 9817 48.0% 0.18 3121 43.9% 2932 41.3% 5.38
U.S. Geographic Region 2
Northeast 1256 18.2% 1255 18.2% 0.04 3339 16.3% 3356 16.4% 0.22 1345 18.9% 1445 20.3% 3.54
Midwest 1624 23.6% 1640 23.8% 0.55 4850 23.7% 4861 23.8% 0.13 1688 23.8% 1613 22.7% 2.50
South 2966 43.1% 2962 43.0% 0.12 9563 46.8% 9580 46.9% 0.17 2999 42.2% 2920 41.1% 2.26
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Table A5. Cont.
Apixaban Cohort Dabigatran Cohort Apixaban Cohort Rivaroxaban Cohort Dabigatran Cohort Rivaroxaban Cohort
n/Mean %/SD n/Mean %/SD STD 1 n/Mean %/SD n/Mean %/SD STD 1 n/Mean %/SD n/Mean %/SD STD 1
West 1008 14.6% 1000 14.5% 0.33 2606 12.8% 2561 12.5% 0.66 1038 14.6% 1098 15.5% 2.36
Other 30 0.4% 27 0.4% 0.68 73 0.4% 73 0.4% 0.00 33 0.5% 27 0.4% 1.30
Race (Only for Humana and
Medicare) 2
White 4361 88.2% 4358 88.1% 0.19 13,910 89.2% 13,926 89.3% 0.33 4368 88.1% 4374 88.2% 0.37
Black 321 6.5% 322 6.5% 0.08 994 6.4% 1001 6.4% 0.18 325 6.6% 318 6.4% 0.57
Other 265 5.4% 267 5.4% 0.18 692 4.4% 669 4.3% 0.72 266 5.4% 267 5.4% 0.09
Baseline Comorbidity
Deyo–Charlson Comorbidity Index
2 3.3 2.8 3.4 2.8 0.27 3.6 2.9 3.6 2.9 0.15 3.3 2.8 3.2 2.7 2.72
CHA2DS2-VASc Score 3.7 1.7 3.7 1.7 0.57 3.9 1.7 3.9 1.7 0.72 3.7 1.7 3.6 1.7 4.04
0 132 1.9% 142 2.1% 1.04 326 1.6% 337 1.6% 0.43 165 2.3% 167 2.4% 0.19
1 442 6.4% 438 6.4% 0.24 988 4.8% 1025 5.0% 0.84 498 7.0% 516 7.3% 0.98
2 1073 15.6% 1032 15.0% 1.65 2722 13.3% 2642 12.9% 1.16 1100 15.5% 1173 16.5% 2.80
3 1531 22.2% 1547 22.5% 0.56 4326 21.2% 4221 20.7% 1.26 1594 22.4% 1612 22.7% 0.61
4+ 3706 53.8% 3725 54.1% 0.55 12,069 59.1% 12,206 59.7% 1.37 3746 52.7% 3635 51.2% 3.13
HAS-BLED Score 3 3.1 1.4 3.1 1.3 2.06 3.2 1.4 3.2 1.4 0.10 3.0 1.4 3.0 1.3 4.61
0 96 1.4% 112 1.6% 1.91 266 1.3% 288 1.4% 0.93 130 1.8% 145 2.0% 1.53
1 695 10.1% 680 9.9% 0.73 1640 8.0% 1662 8.1% 0.40 773 10.9% 821 11.6% 2.14
2 1646 23.9% 1708 24.8% 2.10 4508 22.1% 4555 22.3% 0.55 1771 24.9% 1807 25.4% 1.17
3+ 4447 64.6% 4384 63.7% 1.91 14,017 68.6% 13,926 68.2% 0.96 4429 62.4% 4330 61.0% 2.87
Bleeding History 2 1290 18.7% 1296 18.8% 0.22 4268 20.9% 4265 20.9% 0.04 1317 18.5% 1235 17.4% 3.01
Congestive Heart Failure 2 2459 35.7% 2430 35.3% 0.88 7737 37.9% 7779 38.1% 0.42 2471 34.8% 2451 34.5% 0.59
Diabetes Mellitus 2 3553 51.6% 3645 52.9% 2.68 10,967 53.7% 11,007 53.9% 0.39 3740 52.7% 3773 53.1% 0.93
Hypertension 2 6418 93.2% 6435 93.5% 0.99 19,262 94.3% 19,266 94.3% 0.08 6611 93.1% 6569 92.5% 2.28
Renal Disease 2 1728 25.1% 1690 24.5% 1.28 6072 29.7% 6109 29.9% 0.40 1708 24.0% 1580 22.2% 4.27
Liver Disease 2 448 6.5% 466 6.8% 1.05 1423 7.0% 1379 6.7% 0.85 471 6.6% 474 6.7% 0.17
Myocardial Infarction 2 711 10.3% 706 10.3% 0.24 2400 11.7% 2426 11.9% 0.39 716 10.1% 692 9.7% 1.13
Dyspepsia or Stomach Discomfort 2 1514 22.0% 1505 21.9% 0.32 4826 23.6% 4768 23.3% 0.67 1544 21.7% 1478 20.8% 2.27
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Table A5. Cont.
Apixaban Cohort Dabigatran Cohort Apixaban Cohort Rivaroxaban Cohort Dabigatran Cohort Rivaroxaban Cohort
n/Mean %/SD n/Mean %/SD STD 1 n/Mean %/SD n/Mean %/SD STD 1 n/Mean %/SD n/Mean %/SD STD 1
Non-Stroke/SE Peripheral Vascular
Disease 2 3676 53.4% 3648 53.0% 0.82 11,365 55.6% 11,484 56.2% 1.17 3712 52.3% 3710 52.2% 0.06
Stroke/SE 2 720 10.5% 704 10.2% 0.76 2194 10.7% 2192 10.7% 0.03 711 10.0% 733 10.3% 1.02
Transient Ischemic Attack 2 414 6.0% 427 6.2% 0.79 1316 6.4% 1339 6.6% 0.46 442 6.2% 444 6.3% 0.12
Anemia and Coagulation Defects 2 1873 27.2% 1815 26.4% 1.90 6197 30.3% 6242 30.6% 0.48 1838 25.9% 1709 24.1% 4.20
Alcoholism 2 186 2.7% 195 2.8% 0.80 483 2.4% 471 2.3% 0.39 203 2.9% 221 3.1% 1.49
Peripheral Artery Disease 1350 19.6% 1311 19.0% 1.43 4364 21.4% 4677 22.9% 3.69 1327 18.7% 1463 20.6% 4.82
Coronary Artery Disease 3281 47.7% 3230 46.9% 1.48 10,183 49.8% 10,138 49.6% 0.44 3285 46.2% 3222 45.4% 1.78
Dyslipidemia 2 5560 80.8% 5568 80.9% 0.30 16,857 82.5% 16,842 82.4% 0.19 5716 80.5% 5688 80.1% 0.99
Morbid Obesity 2601 37.8% 2658 38.6% 1.70 7660 37.5% 7896 38.6% 2.38 2726 38.4% 2735 38.5% 0.26
Baseline Medication Use 2
ACEi/ARB 4805 69.8% 4799 69.7% 0.19 14,341 70.2% 14,312 70.1% 0.31 4922 69.3% 4929 69.4% 0.21
Amiodarone 827 12.0% 836 12.1% 0.40 2671 13.1% 2658 13.0% 0.19 849 12.0% 874 12.3% 1.08
Beta Blockers 4287 62.3% 4198 61.0% 2.66 12,981 63.5% 12,917 63.2% 0.65 4311 60.7% 4260 60.0% 1.47
H2-Receptor Antagonist 493 7.2% 477 6.9% 0.91 1496 7.3% 1473 7.2% 0.43 482 6.8% 460 6.5% 1.24
Proton Pump Inhibitor 2301 33.4% 2275 33.0% 0.80 7222 35.3% 7151 35.0% 0.73 2342 33.0% 2259 31.8% 2.50
Statins 4212 61.2% 4193 60.9% 0.57 13,057 63.9% 13,149 64.4% 0.94 4285 60.3% 4189 59.0% 2.75
Anti-Platelets 1312 19.1% 1221 17.7% 3.41 4328 21.2% 4392 21.5% 0.76 1235 17.4% 1150 16.2% 3.20
NSAIDS 2119 30.8% 2122 30.8% 0.09 6191 30.3% 6230 30.5% 0.41 2183 30.7% 2104 29.6% 2.42
Dose of the Index Prescription
Standard Dose 4 6045 87.8% 5979 86.9% 2.88 17,634 86.3% 15,514 75.9% 26.75 6194 87.2% 5698 80.2% 18.99
Low Dose 5 839 12.2% 905 13.1% 2.88 2797 13.7% 4917 24.1% 15.45 909 12.8% 1405 19.8% 7.53
Follow-Up Time (in Days) 176.2 158.3 221.5 218.3 23.72 176.1 159.6 220.4 208.6 23.89 220.7 218.1 217.4 206.4 1.54
Median 120 127 120 141 127 140
ACEi/ARB: angiotensin converting enzyme inhibitors/angiotensin-receptor blockers; CHA2DS2-VASc: congestive heart failure, hypertension, aged ≥ 75 years, diabetes mellitus, prior
stroke or transient ischemic attack or thromboembolism, vascular disease, aged 65–74 years, sex category; HAS-BLED: hypertension, abnormal renal and liver function, stroke, bleeding,
labile international normalized ratios, elderly, drugs and alcohol; NOACs: non-vitamin K oral anticoagulants; NSAIDs: non-steroidal anti-inflammatory drugs; NVAF: non-valvular atrial
fibrillation; PSM: propensity score matching; SD: standard deviation; SE: systemic embolism; STD: standardized difference. 1 Std difference = 100 ×|actual std diff|. Std difference greater
than 10 is considered significant. 2 Variables used in propensity score matching. 3 As the INR value is not available in the databases, a modified HAS-BLED score was calculated with a
range of 0 to 8. 4 Standard dose: 5 mg apixaban, 150 mg dabigatran, 20 mg rivaroxaban. 5 Lower dose: 2.5 mg apixaban, 75 mg dabigatran, 10 or 15 mg rivaroxaban; 950 and 310 patients
were prescribed 10 mg of rivaroxaban in the apixaban-rivaroxaban and dabigatran-rivaroxaban cohorts, respectively.
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Figure A1. Cumulative incidence of major bleeding and stroke/systemic embolism. (A) Major 
bleeding for apixaban vs. warfarin; (B) Stroke/systemic embolism for apixaban vs. warfarin; (C) Major 
bleeding for dabigatran vs. warfarin; (D) Stroke/systemic embolism for dabigatran vs. warfarin; (E) 
Major bleeding for rivaroxaban vs. warfarin; (F) Stroke/systemic embolism for rivaroxaban vs. 
warfarin; (G) Major bleeding for apixaban vs. dabigatran; (H) Stroke/systemic embolism for apixaban 
vs. dabigatran; (I) Major bleeding for apixaban vs. rivaroxaban; (J) Stroke/systemic embolism for 
apixaban vs. rivaroxaban; (K) Major bleeding for dabigatran vs. rivaroxaban; (L) Stroke/systemic 
embolism for dabigatran vs. rivaroxaban. 
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Figure A1. Cumulative incidence of major bleeding and stroke/systemic e bolism. (A) Major bleeding
for apixaban vs. warfarin; (B) Stroke/systemic embolism for apixaban vs. warfarin; (C) Major bleeding
for dabigatran vs. warfarin; (D) Stroke/systemic embolism for dabigatran vs. warfarin; (E) Major
bleeding for rivaroxaban vs. warfarin; (F) Stroke/systemic embolism for rivaroxaban vs. warfarin;
(G) Major bleeding for apixaban vs. dabigatran; (H) Stroke/systemic embolism for apixaban vs.
dabigatran; (I) Major bleeding for apixaban vs. rivaroxaban; (J) Stroke/systemic embolism for apixaban
vs. rivaroxaban; (K) Major bleeding for dabigatran vs. rivaroxaban; (L) Stroke/systemic embolism for
dabigatran vs. rivaroxaban.
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